Editas Medicine announced on January 13, 2025, new in vivo preclinical proof of concept data in non-human primates (NHPs) for editing hematopoietic stem cells (HSCs) and liver cells. The Company also reported in vivo delivery data in humanized mice to two additional target cell types, supporting its gene upregulation strategy.
The Company outlined its anticipated 2025 key milestones, including the expectation to declare two in vivo development candidates by mid-2025, one in HSCs and one in liver cells. Editas Medicine also aims to establish an additional in vivo target cell type or tissue beyond HSCs and the liver by the end of 2025.
As of December 31, 2024, Editas Medicine had approximately $270 million in cash, cash equivalents, and marketable securities. The Company expects this financial position to fund its operating expenses and capital expenditure requirements into the second quarter of 2027.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.